Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.35 |
| ▸ | CCNE2 | O96020 | 9/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
| ▸ | KHK | P50053 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 4/20 | 0.33 |
| ▸ | CCND1 | P24385 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GLP1R | P43220 | 1/20 | 0.32 |
| ▸ | LATS1 | O95835 | 3/20 | 0.31 |
| ▸ | LATS2 | Q9NRM7 | 2/20 | 0.31 |
| ▸ | BCDIN3D | Q7Z5W3 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alcohol SCHEMBL27466006 | 0.92 | SLC29A1 (0.33) | CDK2CCNE2CCNE1LMNAPOLB | |
| SCHEMBL7170682 | 0.84 | GLP1R (0.39) | CDK2CCNE2CCNE1LMNAPOLB | |
| SCHEMBL7172045 | 0.80 | LMNA (0.36) | CDK2CCNE2CCNE1LMNAPOLB | |
| SCHEMBL7859690 | 0.80 | KHK (0.45) | CDK2CCNE2CCNE1LMNAHTT | |
| SCHEMBL7168981 | 0.78 | KHK (0.36) | LMNAKHKMAPTSMN1; SMN2 | |
| SCHEMBL7169151 | 0.73 | CDK2 (0.36) | CDK2CCNE2CCNE1LMNAPOLB | |
| SCHEMBL7171751 | 0.73 | APP (0.38) | KHKGLP1R | |
| SCHEMBL7169449 | 0.72 | BCL6 (0.56) | CDK2LMNAPOLBHTTLATS1 | |
| SCHEMBL7859660 | 0.72 | GLP1R (0.41) | CDK2CCNE2CCNE1LMNAPOLB | |
| SCHEMBL1565794 | 0.71 | KHK (0.46) | LMNAKHKMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1813610-B1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | WAKUNAGA PHARMA CO LTD (JP) | 2010-09-08 | — | — | EP | disclosed |
| US-7713997-B2 | Pyridonecarboxylic acid derivatives or salts thereof | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20090149440-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | WAKUNAGA PHARMACEUTICAL CO., LTD (JP) | 2009-06-11 | — | — | US | disclosed |
| EP-1813610-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
| CN-1196683-C | Amino-compound | YUNAGA PHARMACEUTICAL CO LTD (JP) | 2005-04-13 | — | — | CN | disclosed |
| US-6858625-B1 | Quinolinecarboxylic acid derivative or salts thereof | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2005-02-22 | — | — | US | disclosed |
| CN-1136216-C | Pyrone carboxylic acid derivate or its salt and antibiotic with the same as effective component | ������ҩ��ʽ���� | 2004-01-28 | — | — | CN | disclosed |
| EP-1193266-B1 | QUINOLINECARBOXYLIC ACID DERIVATIVE OR SALTS THEREOF | WAKUNAGA PHARMA CO LTD (JP) | 2003-08-27 | — | — | EP | disclosed |
| EP-0945435-B1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | WAKUNAGA PHARMA CO LTD (JP) | 2003-08-13 | — | — | EP | disclosed |
| US-6586420-B1 | Photostable bactericides | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-01 | — | — | US | disclosed |
| US-6156903-A | Pyridonecarboxylic acid derivatives or their salts, and antibacterial agents containing the same as their effective components | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-05 | — | — | US | disclosed |
| US-6136823-A | BACTERICIDES OR VIRICIDES | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2000-10-24 | — | — | US | disclosed |
| US-6133284-A | EXCELLENT BACTERICIDAL PROPERTIES AND ORAL ABSORPTION; INFECTIONS FROM GRAMNEGATIVE AND -POSITIVE BACTERIA; INTESTINAL ABSORPTION, METABOLIC STABILITY; SIDE EFFECT REDUCTION; NONPHOTOTOXICITY AND NONCYTOTOXICITY | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| CN-1258674-A | Pyrone carboxylic acid derivate or its salt and antibiotic with the same as effective component | YUNAGA PHARMACEUTICAL CO LTD (JP) | 2000-07-05 | — | — | CN | disclosed |
| CN-1258672-A | Amino-compound | YUNAGA PHARMACEUTICAL CO LTD (JP) | 2000-07-05 | — | — | CN | disclosed |
| EP-0992501-A2 | Pyridonecarboxylic acid derivatives as antibacterial agents | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-12 | — | — | EP | disclosed |
| US-5998436-A | Pyridonecarboxylic acid derivatives or their salts and antibacterial agent comprising the same as the active ingredient | WAKUNAGA PHARMACEUTICALS CO., LTD. (JP) | 1999-12-07 | — | — | US | disclosed |
| EP-0952151-A2 | Intermediates for use in preparing novel pyridonecarboxylic acid derivatives or their salts | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-27 | — | — | EP | disclosed |
| EP-0911327-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR THEIR SALTS AND ANTIBACTERIAL AGENT COMPRISING THE SAME AS THE ACTIVE INGREDIENT | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1999-04-28 | — | — | EP | disclosed |
| CN-1201459-A | Novel pyridonecarboxylic acid derivative or salt thereof, and antibacterial agent containing same as active ingredient | WAKUNAGA PHARMA CO LTD (JP) | 1998-12-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149440-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | SLC7A1, PLPBP, PYCR1 | CDK2 1437/4885CCNE2 3675/4885CCNE1 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.